Jazz Pharmaceuticals to Present New Clinical Data on Epidiolex and Xywav at 2026 AAN Annual Meeting

Jazz Pharmaceuticals announced plans to present new research findings on two of its key products, Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, at the 2026 American Academy of Neurology (AAN) Annual Meeting. The company stated that the presentations will focus on clinical data related to these therapies, which are used in the treatment of neurological conditions.

The research highlights will include updates on the efficacy and safety profiles of Epidiolex and Xywav. Epidiolex is approved for managing seizures associated with certain rare forms of epilepsy, while Xywav is indicated for treating cataplexy or excessive daytime sleepiness in patients with narcolepsy. Jazz Pharmaceuticals has not disclosed specific details about the studies but confirmed that the data would provide insights into how these treatments impact patient outcomes. The AAN Annual Meeting serves as a platform for sharing advancements in neurology research and clinical practice.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 9, 2026

Author

GOAI